JPMorgan says the weight-loss drug industry is now a "$100 billion plus opportunity." Coke is one of the stocks they say is likely to get hit less hard.
C WorldWide Thematic Specialist Morten Springborg says his firm has outperformed by taking a much longer-term approach than is usual for money managers.